Dominari Holdings Inc
Change company Symbol lookup
Select an option...
DOMH Dominari Holdings Inc
SMLR Semler Scientific Inc
GME GameStop Corp
DCO Ducommun Inc
QSI Quantum-Si Inc
TLS Telos Corp
ONB Old National Bancorp
TIG Trean Insurance Group Inc
NVDA NVIDIA Corp
DICE Dice Therapeutics Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Dominari Holdings Inc., formerly AIkido Pharma Inc., is a biotechnology company. The Company has a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The Company’s pipeline consists of patented technology from universities and researchers. The Company advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, is a chemotherapy treatment for advanced pancreatic cancer.

Closing Price
$2.98
Day's Change
-0.29 (-8.87%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.36
Day's Low
2.88
Volume
(Heavy Day)
Volume:
63,837

10-day average volume:
33,732
63,837

Ares Capital Corporation Appoints Jana Markowicz as Chief Operating Officer

4:15 pm ET January 19, 2023 (BusinessWire) Print

Ares Capital Corporation ("Ares Capital") (NASDAQ: ARCC) announced today that Jana Markowicz was appointed as its Chief Operating Officer (COO). In this newly created role, Ms. Markowicz will also serve as COO of Ares Management's ("Ares") U.S. Direct Lending strategy where she will collaborate with the U.S. Direct Lending Co-Heads and Investment Committee members in the management of the team and strategy.

Ms. Markowicz joined Ares in 2005 as a member of the U.S. Direct Lending investment team, supporting in the negotiation and origination of private credit transactions. She has been instrumental in the growth of Ares' U.S. Direct Lending strategy, serving as Partner, Head of Product Management and Investor Relations for this strategy and will continue to lead in this capacity as part of her new role. Prior to joining Ares 18 years ago, Ms. Markowicz started her career in Leveraged Finance at Citigroup, formerly Salomon Smith Barney, where she focused on financings for companies across a broad range of industries. She holds a B.S. from the University of Pennsylvania in Engineering, with a concentration in Economic and Financial Systems.

"Jana is a proven leader on our U.S. Direct Lending team with extensive knowledge of our origination, underwriting and portfolio management process," said Kipp deVeer, Chief Executive Officer of Ares Capital. "In her new role as COO, we believe Jana's experience and strategic insights will help us further strengthen our market leading position and enable us to continue generating attractive long-term value for our shareholders."

About Ares Capital Corporation

Founded in 2004, Ares Capital is a leading specialty finance company focused on providing direct loans and other investments in private middle market companies in the United States. Ares Capital's objective is to source and invest in high-quality borrowers that need capital to achieve their business goals, which often leads to economic growth and employment. Ares Capital believes its loans and other investments in these companies can generate attractive levels of current income and potential capital appreciation for investors. Ares Capital, through its investment manager, utilizes its extensive, direct origination capabilities and incumbent borrower relationships to source and underwrite predominantly senior secured loans but also subordinated debt and equity investments. Ares Capital has elected to be regulated as a business development company ("BDC") and is the largest publicly traded BDC by market capitalization as of December 31, 2022. Ares Capital is externally managed by a subsidiary of Ares Management Corporation (NYSE: ARES), a publicly traded, leading global alternative investment manager. For more information about Ares Capital, visit www.arescapitalcorp.com.

Forward-Looking Statements

Statements included herein may constitute "forward-looking statements," which relate to future events or Ares Capital's future performance or financial condition. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results and conditions may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Ares Capital's filings with the Securities and Exchange Commission. Ares Capital undertakes no duty to update any forward-looking statements made herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005821/en/

SOURCE: Ares Capital Corporation

Investors 
Carl G. Drake or John Stilmar
(888) 818-5298
irarcc@aresmgmt.com 

Media 
Brittany Cash, +1-212-301-0347
Jacob Silber, +1 212-301-0376
media@aresmgmt.com
comtex tracking

COMTEX_422949891/1006/2023-01-19T16:15:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.